RE:RE:RE:RE:RE:RE:RE:RE:New PR aroundVM This is from the global patent application with the subject, METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY
From the description;
“Vasculogenic mimicry plays a significant role in tumour growth (42) and it has also been characterized in carcinomas of ovary, breast, lung, liver, colorectal, prostate, bladder, kidney, sarcomas and gliomas (43, 29, 44). Survival analyses indicated that patients with vasculogenic mimicry in their tumors had a poor clinical outcome as compared to patients with tumors that do not exhibit vasculogenic mimicry. Meta-analysis studies evaluating the influence of vasculogenic mimicry on cancer patient survival in 15 types of malignant tumours showed that vasculogenic mimicry was associated with a more aggressive tumor phenotype and a poor 5-year overall survival (24, 43). Recently, it has been reported that cancer stem cells (CSCs) and epithelium-to-endothelium transition, a subtype of epithelial-to-mesenchymal transition, can accelerate vasculogenic mimicry by stimulating cancer cell plasticity, remodeling of the extracellular matrix and connecting vasculogenic mimicry channels to host blood vessels….”
From the claims:
“for use in inhibiting vasculogenic mimicry and/or for treating cancer.
A compound, peptide compound or derivative thereof that specifically binds to a polypeptide having the amino acid sequence as shown in any one of SEQ ID NOs: 25- 50, an analog thereof, or a fragment thereof, for use in inhibiting vasculogenic mimicry.
The compound of any one of claims 1 to 50, wherein the inhibiting vasculogenic mimicry comprises decreasing number of vasculogenic mimicry loops in cancerous tissues or cells expressing Sortilin.
A method of inhibiting vasculogenic mimicry in cancerous tissues or cells expressing Sortilin, comprising contacting said cancerous tissues cells with at least one compound as defined in any one of claims 1 to 57…”
The list goes on and on so this second MOA probably was in their original plans for their PDC now with the “new findings” they probably did the right thing to apply for the patent back in 2019.
WO2020037434 METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY